Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Clene (NASDAQ:CLNN), a late clinical-stage biopharmaceutical company focused on neurodegenerative disease treatments, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City.
The company, which specializes in developing treatments for ALS and multiple sclerosis, will deliver a virtual presentation available for viewing on September 5, 2025. Management will also host one-on-one investor meetings during the conference. Investors can access the presentation through the company's website or register online for the webcast.
Clene (NASDAQ:CLNN), una società biofarmaceutica in fase clinica avanzata focalizzata sui trattamenti per le malattie neurodegenerative, parteciperà al H.C. Wainwright 27th Annual Global Investment Conference dall'8 al 10 settembre 2025 a New York City.
La società, specializzata nello sviluppo di terapie per SLA e sclerosi multipla, terrà una presentazione virtuale disponibile per la visione il 5 settembre 2025. La direzione organizzerà inoltre incontri individuali con gli investitori durante la conferenza. Gli investitori possono accedere alla presentazione dal sito web aziendale o registrarsi online per il webcast.
Clene (NASDAQ:CLNN), una compañía biofarmacéutica en fase clínica avanzada centrada en tratamientos para enfermedades neurodegenerativas, participará en el H.C. Wainwright 27th Annual Global Investment Conference del 8 al 10 de septiembre de 2025 en la ciudad de Nueva York.
La empresa, que desarrolla terapias para la ELA y la esclerosis múltiple, ofrecerá una presentación virtual disponible para su visualización el 5 de septiembre de 2025. La dirección también llevará a cabo reuniones individuales con inversores durante la conferencia. Los inversores pueden ver la presentación en el sitio web de la compañía o registrarse en línea para el webcast.
Clene (NASDAQ:CLNN)는 신경퇴행성 질환 치료제에 주력하는 후기 임상 단계의 바이오제약사로, 2025년 9월 8일부터 10일까지 뉴욕에서 열리는 H.C. Wainwright 27th Annual Global Investment Conference에 참가합니다.
루게릭병(ALS)과 다발성 경화증 치료제 개발을 전문으로 하는 이 회사는 2025년 9월 5일에 시청 가능한 온라인 프레젠테이션을 진행합니다. 경영진은 컨퍼런스 기간 동안 일대일 투자자 미팅도 개최할 예정입니다. 투자자들은 회사 웹사이트를 통해 발표를 시청하거나 웹캐스트에 온라인으로 등록할 수 있습니다.
Clene (NASDAQ:CLNN), une société biopharmaceutique en phase clinique avancée spécialisée dans les traitements des maladies neurodégénératives, participera à la H.C. Wainwright 27th Annual Global Investment Conference du 8 au 10 septembre 2025 à New York.
La société, qui développe des traitements pour la SLA et la sclérose en plaques, présentera une intervention virtuelle disponible le 5 septembre 2025. La direction organisera également des rencontres individuelles avec des investisseurs pendant la conférence. Les investisseurs peuvent accéder à la présentation via le site web de la société ou s'inscrire en ligne au webinaire.
Clene (NASDAQ:CLNN), ein biopharmazeutisches Unternehmen in der späten klinischen Phase mit Fokus auf Therapien für neurodegenerative Erkrankungen, wird vom 8. bis 10. September 2025 an der H.C. Wainwright 27th Annual Global Investment Conference in New York City teilnehmen.
Das Unternehmen, das sich auf die Entwicklung von Behandlungen für ALS und Multiple Sklerose spezialisiert hat, hält eine virtuelle Präsentation, die am 5. September 2025 abrufbar sein wird. Das Management wird während der Konferenz außerdem Einzelgespräche mit Investoren führen. Investoren können die Präsentation über die Unternehmenswebsite ansehen oder sich online für das Webcast registrieren.
- None.
- None.
SALT LAKE CITY, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the H.C. Wainwright 27th Annual Global Investment Conference and host 1x1 investor meetings.
Date: September 8-10, 2025
Location: New York City, NY
Format: Virtual Presentation available for viewing on September 5, 2025
1x1 Meetings: Please contact your H.C. Wainwright representative
A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register online to view the webcast here: link
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
Investor Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
617-283-2856
FAQ
When is Clene (CLNN) presenting at the H.C. Wainwright Conference 2025?
What diseases does Clene (CLNN) focus on treating?
How can investors access Clene's H.C. Wainwright conference presentation?
What type of meetings will Clene (CLNN) host at the H.C. Wainwright conference?
